Johnson & Johnson $JNJ (+2,5 %) has achieved important goals in a phase 3 study with its drug for the treatment of skin diseases. The drug, an IL-23 inhibitor, showed a significant improvement in patients with moderate to severe psoriasis compared to placebo in the study. These results underline the therapy's potential to expand existing treatment options.

Further information can be found in the article on Reuters.

The news is based on what I personally consider to be reputable sources. However, I do not guarantee their accuracy. No advice.